Palisade Bio (PALI) Total Non-Current Liabilities (2012 - 2026)
Palisade Bio (PALI) posted quarterly Total Non-Current Liabilities of $5.7 million for Q1 2026, up 98.88% year-over-year from $2.9 million in Q1 2025, and up 20.95% quarter-over-quarter from $4.7 million in Q4 2025.
Palisade Bio (PALI) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Palisade Bio (PALI) has reported Total Non-Current Liabilities for 15 consecutive years, with $5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 98.88% year-over-year to $5.7 million; the TTM figure through Mar 2026 stood at $5.7 million (up 98.88% YoY), while the FY2025 annual figure was $4.7 million, up 45.09% from the prior year.
- Total Non-Current Liabilities improved to $5.7 million in Q1 2026 per PALI's latest filing, from $4.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.7 million in Q1 2026 and bottomed at $1.5 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $3.2 million across 5 years, with a median of $2.9 million in 2024.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities dropped 26.09% — and 2026, when it surged 98.88%.
- Palisade Bio's Total Non-Current Liabilities stood at $3.3 million in 2022, then declined by 16.66% to $2.7 million in 2023, then rose by 18.3% to $3.2 million in 2024, then soared by 45.09% to $4.7 million in 2025, then rose by 20.95% to $5.7 million in 2026.
- Business Quant data shows PALI's Total Non-Current Liabilities at $5.7 million in Q1 2026, $4.7 million in Q4 2025, and $3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Palisade Bio | 372.94 Mn | 247.74 Mn | - | 5.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.25 Mn |
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 3.97 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 3.24 Mn |
| Sep 30, 2024 | 2.68 Mn |
| Jun 30, 2024 | 2.86 Mn |
| Mar 31, 2024 | 2.59 Mn |
| Dec 31, 2023 | 2.74 Mn |
| Sep 30, 2023 | 2.77 Mn |
| Jun 30, 2023 | 2.49 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 3.75 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 1.86 Mn |
| Dec 31, 2021 | 2.50 Mn |
| Sep 30, 2021 | 2.92 Mn |